Chugai Pharmaceutical Co.

Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024: Insights On 10 Current & Potential Proprietary Platforms, Company, Indication & Phase for 15 Drugs, and 14 Companies - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 1, 2024

The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024 Report Finding & Highlights:
    Insight On Current & Potential DLL3 Targeted Therapies Proprietary Platforms: > 10 Platform
    DLL3 Targeted Drugs Clinical Trials Insight By Company, Indication & Phase: > 15 Drugs
    Insight On Companies Involved In R&D Of DLL3 Targeted Therapies: 14 Companies
    In recent years, the discovery of Delta Like Ligand 3 (DLL3) as a therapeutic cancer target has emerged as key defining moment in the targeted therapy landscape.
  • Stemcentrx, now a subsidiary of AbbVie, led the development of Rovalpituzumab tesirine (Rova-T), which was a pioneering endeavor in the field of DLL3 targeted therapies.
  • The dynamic evolution of DLL3 targeted therapies is characterized by a wide range of candidates in clinical trials, extending far beyond Rovalpituzumab conjugates.

Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout

Retrieved on: 
Monday, October 16, 2023

After this round of financing, Atom has raised a total of nearly $165 million.

Key Points: 
  • After this round of financing, Atom has raised a total of nearly $165 million.
  • "We appreciate the support of every investment institution involved in the D-round financing and previous investors,” said Dr. William Dongfang Shi, CEO, Chairman and Founder of Atom Bioscience.
  • Maintaining sUA levels of 5 mg/dL to 4 mg/dL in gout patients is recommended by many national gout treatment guidelines.
  • At these levels gout tophi are re-dissolved, tophi size and quantity are reduced and eventually acute gout attacks are reduced.

Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout

Retrieved on: 
Monday, October 9, 2023

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3 clinical trial of ABP-671, a novel orally administered URAT1 inhibitor, for the treatment of chronic gout.

Key Points: 
  • Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3 clinical trial of ABP-671, a novel orally administered URAT1 inhibitor, for the treatment of chronic gout.
  • Part 2 of the study will be a confirmatory study for dosing regimens of ABP-671 selected from Part 1.
  • “Gout affects more than 50 million people worldwide and is on the rise in many countries,” said Atom Bioscience CEO, Chairman and Founder Dr. William Dongfang Shi.
  • At these levels gout tophi are re-dissolved, tophi size and quantity are reduced and eventually acute gout attacks are reduced.

AlphaSense Continues Global Expansion in Asia Pacific with New Regional Hub in Singapore

Retrieved on: 
Wednesday, August 23, 2023

NEW YORK, Aug. 23, 2023 /PRNewswire/ -- AlphaSense, the leading market intelligence and search platform, today announced its continued expansion in the Asia-Pacific (APAC) region with a new regional hub in Singapore. The expansion, in response to strong customer demand in the region, will support AlphaSense's growing global footprint, enabling the company to better serve its existing APAC client base while bolstering its capacity to scale customer growth.

Key Points: 
  • AlphaSense today announced its continued expansion in the Asia-Pacific region with a new regional hub in Singapore.
  • Customers in the region include Chugai Pharmaceutical, Samsung, Petronas, HSBC, Hong Kong's Sylebra Capital, Singapore's YH2 Capital Management, and many more.
  • Currently, users can search in the AlphaSense platform across non-English content in eight different languages, including Japanese, Korean, and Simplified Chinese.
  • The expansion into APAC is the most recent example of AlphaSense's expanding global footprint—in September 2022, AlphaSense opened an office in Germany, adding to its existing footprint in the U.S., U.K., Finland, and India.

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Retrieved on: 
Thursday, July 27, 2023

CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity’s leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023. He will remain as a member of Vaxxinity’s board of directors.

Key Points: 
  • CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity’s leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023.
  • Peter will oversee the overall scientific direction of Vaxxinity’s platform and programs, and lead the development efforts at Vaxxinity.
  • “Get ready for the next wave of innovative drug science at Vaxxinity,” said Mei Mei Hu, CEO of Vaxxinity.
  • We look forward to continuing to work with Ulo and to benefit from his expertise in his role as an advisor to Vaxxinity.”

Atom Bioscience Marks Gout Awareness Day by Urging Increased Patient Education on Debilitating Effects of the Chronic Disease

Retrieved on: 
Monday, May 22, 2023

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of gout to help mark Gout Awareness Day, May 22, 2023.

Key Points: 
  • Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of gout to help mark Gout Awareness Day, May 22, 2023.
  • Dr. William Shi, Founder and CEO of Atom Bioscience stated, “In treating gout, we have to do more than ease the painful symptoms of gout flare-ups.
  • The build-up of uric acid is caused by genetic mutations in uric acid transport mechanisms in the kidney and bowel.
  • Excessive uric acid can lead to the formation of crystals in joints and soft tissues, causing debilitating inflammation and the development of urate kidney stones.

2023 ISPE Facility of the Year Awards (FOYA) Category Winners Announced

Retrieved on: 
Wednesday, May 10, 2023

NORTH BETHESDA, Md., May 9, 2023 /PRNewswire-PRWeb/ -- ISPE today announced the 2023 Facility of the Year Awards (FOYA) Winners at the 2023 ISPE Europe Annual Conference in Amsterdam, The Netherlands. The award-winning projects selected by the FOYA program set the standard for pharmaceutical facilities of the future by demonstrating excellence in facility design, construction, and operations.

Key Points: 
  • The Innovation Category was awarded to Chugai Pharma Manufacturing Co., Ltd. for its facility in Shizuoka Pref, Japan for the FJ2 Project.
  • Chugai implemented several innovative design and equipment concepts in the facility to protect both the product and the worker.
  • The Operations Category was awarded to WuXi Biologics Ireland Limited for its Contract Research, Development and Manufacturing Organization (CRDMO) facility in County Louth, Ireland.
  • The 2023 FOYA Category Winners will be formally recognized at the ISPE Facility of the Year Awards Banquet and Dinner on 15 October 2023, in Las Vegas, Nevada, where the 2023 FOYA Overall Winner will also be announced.

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

Retrieved on: 
Wednesday, April 26, 2023

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente, M.D., to Executive Vice President, Chief Development Officer.
  • In her new role, effective May 1, 2023, she will be responsible for leading Xencor’s clinical and medical strategy and execution.
  • Allen Yang, M.D., Ph.D., Chief Medical Officer, will continue to advise the Company and after a transition period will leave Xencor to pursue other opportunities.
  • “During her time on our Board, Nancy gained a deep understanding of our XmAb® platforms, portfolio strategy, development programs, and people, and we are delighted that she has chosen to join our senior management team,” said Bassil Dahiyat, Ph.D., President and Chief Executive Officer at Xencor.

Devic's Syndrome Treatment Global Market Report 2022: Soliris (Eculizumab) to Foster Growth in the Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 22, 2023

Soliris works by specifically preventing activation of particular proteins in the complement system (C5a and C5b), which play a role in the treatment of Devic s syndrome.

Key Points: 
  • Soliris works by specifically preventing activation of particular proteins in the complement system (C5a and C5b), which play a role in the treatment of Devic s syndrome.
  • Patients suffering with Devic's syndrome possess AQP4 antibody-positive, the body s immune system can turn against itself to produce autoantibodies against AQP4.
  • There are three promising molecules in Devic s syndrome treatment pipeline such as Satralizumab - Phase 3 (Hoffmann-La Roche/ Chugai Pharmaceutical), MEDI-551- Phase 2/3 (MedImmune LLC), and RC18 - Phase 3 (RemeGen, Ltd.).
  • According to National Multiple Sclerosis Society, there are around 4,000 people suffering with Devic's syndrome in the United States with majority of women population.

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

Retrieved on: 
Thursday, March 2, 2023

Since pain is a subjective symptom, it can be difficult to accurately convey to family members and healthcare professionals the degree of pain patients experience.

Key Points: 
  • Since pain is a subjective symptom, it can be difficult to accurately convey to family members and healthcare professionals the degree of pain patients experience.
  • The collaboration will focus on:
    Virtual specialty care delivery by Biofourmis for endometriosis patients in the U.S.
  • Our focus is on solving the biggest pain points in care delivery and pharma R&D, and this patient-centered collaboration with Chugai is a leading example."
  • Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology (Press Release on July 22, 2020)